FILAMENT HEALTH ANNOUNCES SECOND QUARTER 2025 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS

VANCOUVER, BC, Aug. 11, 2025 /CNW/ - Filament Health Corp. (OTC: FLHLF) ("Filament" or the "Company"), a clinical‐stage natural psychedelic drug development company, released its second quarter financial results and operational highlights for the period ended June 30, 2025.

"This quarter, we took deliberate steps to position Filament Health for long-term growth, including streamlining our public listings to reduce costs and increase operational efficiency. We advanced our clinical and licensing portfolio with two significant developments: securing an exclusive global license for intellectual property and data usage from a Phase 2 study of psilocybin as a treatment for cocaine use disorder, and receiving approval to initiate a Phase 2 trial of our botanical psilocybin drug candidate, PEX010, for the treatment of prolonged brief disorder in Sweden," said Benjamin Lightburn, Chief Executive Officer and Co-Founder at Filament Health. "These achievements reflect our commitment to pioneering psychedelic drug development while managing our resources strategically, ensuring that we are well-positioned to continue delivering on our mission. The demand for botanical psychedelic treatments ...